Genocea Biosciences Stock Shares Owned By Insiders
| GNCADelisted Stock | USD 0.0002 0.0001 100.00% |
Genocea Biosciences fundamentals help investors to digest information that contributes to Genocea Biosciences' financial success or failures. It also enables traders to predict the movement of Genocea Stock. The fundamental analysis module provides a way to measure Genocea Biosciences' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Genocea Biosciences stock.
Genocea |
Genocea Biosciences Company Shares Owned By Insiders Analysis
Genocea Biosciences' Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.
More About Shares Owned By Insiders | All Equity Analysis
Insiders Shares | = | Executives Shares | + | Employees |
Current Genocea Biosciences Shares Owned By Insiders | 6.22 % |
Most of Genocea Biosciences' fundamental indicators, such as Shares Owned By Insiders, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Genocea Biosciences is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Although the research on effects of insider trading on prices and volatility is still relatively inconclusive, and investors are advised to pay close attention to the distribution of equities among company's stakeholders to avoid many problems associated with the disclosure of price-sensitive information.
CompetitionBased on the latest financial disclosure, 6.222% of Genocea Biosciences are shares owned by insiders. This is 59.01% lower than that of the Biotechnology sector and 56.12% lower than that of the Health Care industry. The shares owned by insiders for all United States stocks is 38.33% higher than that of the company.
Genocea Shares Owned By Insiders Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Genocea Biosciences' direct or indirect competition against its Shares Owned By Insiders to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Genocea Biosciences could also be used in its relative valuation, which is a method of valuing Genocea Biosciences by comparing valuation metrics of similar companies.Genocea Biosciences is currently under evaluation in shares owned by insiders category among its peers.
Genocea Fundamentals
| Return On Equity | -5.26 | |||
| Return On Asset | -0.58 | |||
| Operating Margin | (29.59) % | |||
| Current Valuation | (4.53 M) | |||
| Shares Outstanding | 58.78 M | |||
| Shares Owned By Insiders | 6.22 % | |||
| Shares Owned By Institutions | 1.25 % | |||
| Number Of Shares Shorted | 1.64 M | |||
| Price To Earning | (0.59) X | |||
| Price To Book | 0.01 X | |||
| Price To Sales | 0.12 X | |||
| Revenue | 1.64 M | |||
| Gross Profit | 1.64 M | |||
| EBITDA | (34.32 M) | |||
| Net Income | (33.2 M) | |||
| Cash And Equivalents | 20.14 M | |||
| Cash Per Share | 0.34 X | |||
| Total Debt | 8.79 M | |||
| Debt To Equity | 1.25 % | |||
| Current Ratio | 1.35 X | |||
| Book Value Per Share | 0.21 X | |||
| Cash Flow From Operations | (45.37 M) | |||
| Short Ratio | 0.74 X | |||
| Earnings Per Share | (0.53) X | |||
| Target Price | 3.08 | |||
| Number Of Employees | 74 | |||
| Beta | 1.6 | |||
| Market Capitalization | 5.88 K | |||
| Total Asset | 55.97 M | |||
| Retained Earnings | (339.66 M) | |||
| Working Capital | 69.32 M | |||
| Current Asset | 76.41 M | |||
| Current Liabilities | 7.09 M | |||
| Z Score | -7.2 | |||
| Net Asset | 55.97 M |
About Genocea Biosciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Genocea Biosciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Genocea Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Genocea Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.
Other Consideration for investing in Genocea Stock
If you are still planning to invest in Genocea Biosciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Genocea Biosciences' history and understand the potential risks before investing.
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities |